CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Berlin, Germany and 388 other locations
survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Wo...
Phase 3
Berlin, Germany and 322 other locations
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means tha ...
Phase 3
Berlin, Germany and 302 other locations
hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with on ...
Phase 3
Berlin, Germany and 278 other locations
vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to ...
Phase 3
Berlin, Germany and 115 other locations
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...
Phase 3
Berlin, Germany and 407 other locations
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...
Phase 3
Berlin, Germany and 320 other locations
The purpose of this clinical phase 3 randomized trial is to compare two different dosing schedules of Docetaxel in combination with ADT and Darolutam...
Phase 3
Berlin, Germany and 42 other locations
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer....
Phase 3
Berlin, Germany and 396 other locations
abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Grou...
Phase 3
Berlin, Germany and 308 other locations
Clinical trials
Research sites
Resources
Legal